Marc L. Berger, MD

Articles by Marc L. Berger, MD

GRACE Principles: Recognizing High-Quality Observational Studies of Comparative Effectiveness

ByNancy A. Dreyer, PhD,Sebastian Schneeweiss, MD,Barbara J. McNeil, MD,Marc L. Berger, MD,Alec M. Walker, MD,Daniel A. Ollendorf, MPH,Richard E. Gliklich, MD,for the GRACE Initiative

June 4th 2010

The GRACE principles lay out 3 questions to help healthcare providers, patients, and other decision makers evaluate the quality of noninterventional comparative effectiveness studies.

Do Drug Formulary Policies Reflect Evidence of Value?

ByPeter J. Neumann, ScD,Pei-Jung Lin, MS,Dan Greenberg, PhD,Marc L. Berger, MD,Steven M. Teutsch, MD,Edward Mansley, PhD,Milton C. Weinstein, PhD,Allison B. Rosen, MD, ScD

January 1st 2006

Impact of 3-Tier Pharmacy Benefit Design and Increased Consumer Cost-sharing on Drug Utilization

ByPamela B. Landsman, MPH, DrPH,Winnie Yu, PharmD,XiaoFeng Liu, PhD,Steven M. Teutsch, MD,Marc L. Berger, MD

October 1st 2005

Indirect Cost of Ischemic Heart Disease to Employers

ByBruce Sherman, MD. Author Reply by Christine J. Guico-Pabia, MD, MBA,James F. Murray, PhD,Marc L. Berger, MD,Steven M. Teutsch, MD, MPH

April 1st 2001

Indirect Cost of Ischemic Heart Disease to Employers

ByChristine J. Guico-Pabia, MD, MBA,James F. Murray, PhD,Steven M. Teutsch, MD, MPH,Albert I. Wertheimer, PhD, MBA,Marc L. Berger, MD

January 1st 2001

The Cholesterol Population Model: US Population Requirements for Treatment of Hypercholesterolemia

ByRobert S. Epstein, MD, MS,Susan Garrahan,Linda Nelsen, MS,Pamela Laber,Eve Slater, MD,Marc L. Berger, MD

December 1st 1996

Latest Updated Articles

Do Drug Formulary Policies Reflect Evidence of Value?
January 1st 2006
Indirect Cost of Ischemic Heart Disease to Employers
January 1st 2001
The Cholesterol Population Model: US Population Requirements for Treatment of Hypercholesterolemia
December 1st 1996
Indirect Cost of Ischemic Heart Disease to Employers
April 1st 2001
GRACE Principles: Recognizing High-Quality Observational Studies of Comparative Effectiveness
June 4th 2010
Impact of 3-Tier Pharmacy Benefit Design and Increased Consumer Cost-sharing on Drug Utilization
October 1st 2005

Marc L. Berger, MD

Articles by Marc L. Berger, MD

GRACE Principles: Recognizing High-Quality Observational Studies of Comparative Effectiveness

Do Drug Formulary Policies Reflect Evidence of Value?

Impact of 3-Tier Pharmacy Benefit Design and Increased Consumer Cost-sharing on Drug Utilization

Indirect Cost of Ischemic Heart Disease to Employers

Indirect Cost of Ischemic Heart Disease to Employers

The Cholesterol Population Model: US Population Requirements for Treatment of Hypercholesterolemia

Latest Updated Articles

Trending on AJMC

FDA Approves Atacicept for IgA Nephropathy

Ebola Cases Top 1700 as Unpaid Health Workers Strike

340B Drug Payment Cuts Headline CMS Proposal to Lower Medicare Costs

Quest Adds Haystack MRD to OncoEMR for Community Oncology

IL-6, Not hsCRP, Modified Lp(a)-Associated CAD Risk

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Marc L. Berger, MD

Articles by Marc L. Berger, MD

GRACE Principles: Recognizing High-Quality Observational Studies of Comparative Effectiveness

Do Drug Formulary Policies Reflect Evidence of Value?

Impact of 3-Tier Pharmacy Benefit Design and Increased Consumer Cost-sharing on Drug Utilization

Indirect Cost of Ischemic Heart Disease to Employers

Indirect Cost of Ischemic Heart Disease to Employers

The Cholesterol Population Model: US Population Requirements for Treatment of Hypercholesterolemia

Latest Updated Articles

Trending on AJMC

FDA Approves Atacicept for IgA Nephropathy

Ebola Cases Top 1700 as Unpaid Health Workers Strike

340B Drug Payment Cuts Headline CMS Proposal to Lower Medicare Costs

Quest Adds Haystack MRD to OncoEMR for Community Oncology

IL-6, Not hsCRP, Modified Lp(a)-Associated CAD Risk